secwatch.observer — SEC 8-K summary
======================================

Issuer:     UTAH MEDICAL PRODUCTS INC (UTMD)
CIK:        0000706698
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001096906-23-000240
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01, 99.1
LLM model:  deepseek-v4-flash:cloud@v2

UTMD Q4 EPS $1.253, up 11% YoY; FY22 EPS $4.522, up 12%; dividend raised to $0.295
--------------------------------------------------------------------------------

- Q4 revenue $13.6M (+5.1% YoY); FY22 revenue $52.3M (+6.6% YoY); constant currency sales up ~10% for the year.
- Gross margin declined to 61.3% (Q4) and 61.6% (FY22) from 62.8%/63.0% on higher manufacturing costs and raw materials.
- FY22 operating income $19.8M (+4.8%) despite $670K in litigation expenses vs $22K in 2021; cash & investments rose to $75.1M.
- Repurchased 30,105 shares at $82.88 in Q2 2022; quarterly dividend increased to $0.295/share effective Jan 2023 payment.
- Outstanding shares 3.63M at year-end; diluted shares 3.64M; no debt on balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/706698/000109690623000240/0001096906-23-000240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/706698/000109690623000240/utmd-20230131.htm
  HTML page:      https://secwatch.observer/filing/0001096906-23-000240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer